Shahrad Daraeikia is a scientist and strategist with nearly a decade of experience in antibody discovery and protein engineering. He has focused his career on developing next-generation antibody display libraries, as well as platforms for affinity maturation and humanization. Today, he applies his lab-based expertise in a commercial setting—helping partners identify tailored solutions for complex antibody discovery and engineering programs. Shahrad excels at bridging deep scientific insight with practical application, fostering collaborative partnerships that advance the boundaries of therapeutic antibody development. He holds 6 US patents for novel design in antibody engineering against SARS-CoV-2.
Shahrad graduated from the University of San Francisco with a Professional Science Master's degree in Biotechnology.